Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gross Profit: 2016-2024

Historic Gross Profit for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Dec 2024 value amounting to $483.5 million.

  • Ultragenyx Pharmaceutical's Gross Profit rose 11.37% to $131.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.0 million, marking a year-over-year increase of 18.45%. This contributed to the annual value of $483.5 million for FY2024, which is 24.28% up from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's Gross Profit stood at $483.5 million, which was up 24.28% from $389.0 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's Gross Profit's 5-year high stood at $483.5 million during FY2024, with a 5-year trough of $264.9 million in FY2020.
  • Moreover, its 3-year median value for Gross Profit was $389.0 million (2023), whereas its average is $402.5 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Gross Profit surged by 179.71% in 2020, and later declined by 0.12% in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Gross Profit (Yearly) stood at $264.9 million in 2020, then climbed by 26.61% to $335.4 million in 2021, then fell by 0.12% to $335.0 million in 2022, then grew by 16.13% to $389.0 million in 2023, then increased by 24.28% to $483.5 million in 2024.